Gilead Sciences and Mylan have for years had a deal for Mylan to make generic versions of some of Gilead's HIV drugs in markets around the world. Now Mylan will take over distribution of Gilead's branded products in India, a country where high-cost meds have sometimes met patent challenges.
AstraZeneca notched an antibiotics research deal with a licensing/option set-up with FOB Synthesis, covering combinations of the two companies' experimental drugs.
Lechleiter recently pointed to animal health as well as key therapeutic areas like neurosciences, diabetes and cancer, according to a report from Reuters.
Germany's Medigene AG has nabbed a small cancer vaccine developer in a buyout which will add a team of investigators from one of the country's top research institutes. Medigene agreed to pay about 4 million euros in stock for Trianta Immunotherapies, with another 6 million euro chunk held aside for possible milestone payments.
After buying Nanostim just a few months ago, St. Jude Medical has implanted the company's eponymous leadless pacemaker in a patient in the U.K., a global first for a wireless device of its kind postapproval.
After a few lean years of tepid dealmaking, biopharma M&A roared back in 2013, as ever-inflating price tags brought in big numbers despite a drop in buyouts. Now, as valuations keep their skyward pace, the industry might be in line for some sticker shock in 2014.
Quest Diagnostics acquired Solstas Lab Partners Group from private equity partner Welsh, Carson, Anderson and Stowe for approximately $570 million, according to a company statement released on Wednesday.
Ariad Pharmaceuticals just relaunched its leukemia drug Iclusig last week, but already buyout rumors are buzzing. The U.S.-based biotech saw its shares jump this morning on reports that Eli Lilly is leading a field of several potential buyers.
Market rumors about a possible biotech buyout are usually triggered by research and marketing success. In Ariad's case, mere survival sufficed.
Quest Diagnostics is making another acquisition. The provider of diagnostic tests and services said it will pay $570 million to private equity partner Welsh, Carson, Anderson and Stowe for Solstas Lab Partners Group.